NEW YORK, June 20, 2008 (PRIME NEWSWIRE) -- By 2020 the pharmaceutical research and development (R&D) process may be shortened by two-thirds, success rates may dramatically increase and clinical trial costs could be cut substantially, according to a report issued today by PricewaterhouseCoopers entitled Pharma 2020: Virtual R&D, which path will you take?
